🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 7

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 7 of 8
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
May 17, 2026 at 10:17 AM#31
Dr.LipidDallas said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

There is a second half to this that has not been said yet. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: May 17, 2026 at 12:17 PM
24 24Dr.EndoEP, GraceAZ_72, carl_compliance and 21 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
May 19, 2026 at 11:59 AM#32

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Last edited: May 19, 2026 at 1:59 PM
23 23Dr.ObesityLA, NurseKim_ATL, paul_denver and 20 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
May 21, 2026 at 1:39 PM#33

A narrower follow-up, since the general answer is now clear:

What did you change at the same time, and can you separate the two now?

Last edited: May 21, 2026 at 7:39 PM
22 22kevin_tulsa, Dr.PainCLE, mike_mealprep and 19 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
May 23, 2026 at 3:18 PM#34
lucas_SP_BR said:
If you are going to change something, change one thing and give it long enough to express itself.

Pushing back on lucas_SP_BR here. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

21 21labquiet_amy, emily_PDX, Dr.SleepRoch and 18 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
May 25, 2026 at 4:57 PM#35
lucas_SP_BR said:
If you are going to change something, change one thing and give it long enough to express itself.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

Last edited: May 25, 2026 at 7:57 PM
20 20bbq_ray_KC, oliver_london, tane_welly and 17 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register